Synthesis, hydrolysis kinetics and anti-platelet effects of isosorbide mononitrate derivatives of aspirin

被引:22
作者
Gilmer, JF [1 ]
Moriarty, LM
McCafferty, DMF
Clancy, JM
机构
[1] Univ Dublin Trinity Coll, Dept Pharmaceut Chem, Sch Pharm, Dublin 2, Ireland
[2] Queens Univ Belfast, Dept Pharmaceut, Sch Pharm, Ctr Med Biol, Belfast BT9 7BL, Antrim, North Ireland
关键词
prodrug; aspirin; ISMN; nitric oxide; platelet inhibition;
D O I
10.1016/S0928-0987(01)00183-X
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Two isomeric aspirin derivatives of isosorbide-5-mononitrate (ISMN) were prepared and evaluated as potential mutual prodrugs of aspirin and nitric oxide. The hydrolysis of both compounds was studied in pH 7.4 phosphate buffer solution, buffered alpha -chymotrypsin solution and 10% buffered rabbit plasma. The benzodioxin-4-one derivative was hydrolysed to salicylic acid and ISMN acetate in buffer solution (t(1/2) 32. t h), 10% buffered rabbit plasma (t(1/2) 25.7 min) and alpha -chymotrypsin (t(1/2) 86.6 min). The carboxylic acid ester derivative ISMNA was hydrolysed via the salicylate ester in buffer solution (t(1/2) 48.5 h) but was rapidly and almost exclusively hydrolysed to aspirin and ISMN in plasma solution (t(1/2) 2.8 min). The hydrolysis appeared to be enzyme mediated as it was suppressed by co-incubation with eserine. ISMNA was evaluated for its ability to inhibit platelet aggregation in rabbit PRP in response to the following agonists: arachidonic acid (AA) (100 muM), ADP (1.2 muM) phorbol ester (0.5 muM). platelet activating factor (PAF) (5 nM) and the thromboxane mimic U46619 (1.5 muM). ISMNA suppressed platelet response to AA at 1 muM whereas 10 muM aspirin showed no inhibitory effects. (C) 2001 Published by Elsevier Science B.V.
引用
收藏
页码:221 / 227
页数:7
相关论文
共 29 条
[1]  
ANKERSEN M, 1989, ACTA CHEM SCAND, V34, P213
[2]  
[Anonymous], 1994, BMJ
[3]   AGGREGATION OF BLOOD PLATELETS BY ADENOSINE DIPHOSPHATE AND ITS REVERSAL [J].
BORN, GVR .
NATURE, 1962, 194 (4832) :927-&
[4]  
CRYER B, 1995, GASTROENTEROLOGY, V108, pA77, DOI 10.1016/0016-5085(95)22971-X
[5]   DOES NON-ACETYLATED SALICYLATE INHIBIT THROMBOXANE BIOSYNTHESIS IN HUMAN-PLATELETS [J].
DANESH, BJZ ;
MCLAREN, M ;
RUSSELL, RI ;
LOWE, GDO ;
FORBES, CD .
SCOTTISH MEDICAL JOURNAL, 1988, 33 (04) :315-316
[6]   NO-aspirins: a class of new antiinflammatory and antithrombotic agents [J].
del Soldato, P ;
Sorrentino, R ;
Pinto, A .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1999, 20 (08) :319-323
[7]   CHEMICAL FEASIBILITY STUDIES CONCERNING POTENTIAL PRODRUGS OF ACETYLSALICYLIC-ACID [J].
HANSEN, AB ;
SENNING, A .
ACTA CHEMICA SCANDINAVICA SERIES B-ORGANIC CHEMISTRY AND BIOCHEMISTRY, 1983, 37 (04) :351-359
[8]   ENZYMATIC AND NONENZYMATIC INVITRO HYDROLYSIS OF 2-METHYL-2-[2-(METHOXY)PHENOXY]-4H-1,3-BENZODIOXIN-4-ONE AND 2-METHOXYPHENYL O-ACETYLSALICYLATE [J].
HUNDEWADT, M ;
SENNING, A .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1991, 80 (06) :545-547
[9]   ASPIRIN PRODRUGS - 2-METHYL-2-ARYLOXY-4H-1,3-BENZODIOXIN-4-ONES ACTING AS TRUE ASPIRIN PRODRUGS [J].
HUNDEWADT, M ;
SENNING, A .
ACTA CHEMICA SCANDINAVICA, 1990, 44 (07) :746-751
[10]  
ICH, 1994, INT C HARM TECHN REQ